In its upcoming report, Alnylam Pharmaceuticals (ALNY) is predicted by Wall Street analysts to post quarterly earnings of $2.05 per share, reflecting an increase of 540.6% compared to the same period last year. Revenues are forecasted to be $1.32 billion, representing a year-over-year increase of 70.4%.
Over the last 30 days, there has been an upward revision of 2% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Before a company reveals its earnings, it is vital to take into account any changes in earnings projections. These revisions play a pivotal role in predicting the possible reactions of investors toward the stock. Multiple empirical studies have consistently shown a strong association between trends in earnings estimates and the short-term price movements of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
With that in mind, let's delve into the average projections of some Alnylam metrics that are commonly tracked and projected by analysts on Wall Street.
Analysts' assessment points toward 'Revenues- Product revenues, net' reaching $1.21 billion. The estimate points to a change of +80.2% from the year-ago quarter.
Analysts expect 'Revenues- Net revenues from collaborations' to come in at $51.11 million. The estimate points to a change of -16.9% from the year-ago quarter.
Based on the collective assessment of analysts, 'Revenues- Royalty revenue' should arrive at $56.25 million. The estimate suggests a change of +40.7% year over year.
The consensus among analysts is that 'Net Product Revenue- Oxlumo' will reach $53.69 million. The estimate points to a change of +14.5% from the year-ago quarter.
The average prediction of analysts places 'Net Product Revenue- Givlaari' at $82.64 million. The estimate suggests a change of +2.2% year over year.
The collective assessment of analysts points to an estimated 'Net Product Revenue- Onpattro' of $24.19 million. The estimate points to a change of -53.7% from the year-ago quarter.
Analysts forecast 'Net Product Revenue- Amvuttra' to reach $1.05 billion. The estimate indicates a year-over-year change of +113.3%.
View all Key Company Metrics for Alnylam here>>>Shares of Alnylam have demonstrated returns of -5.2% over the past month compared to the Zacks S&P 500 composite's +1.7% change. With a Zacks Rank #3 (Hold), ALNY is expected to mirror the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Alnylam Pharmaceuticals, Inc. (ALNY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).